Darapladib
CAS No. : 356057-34-6
(Synonyms: SB-480848)
| Size | Price | Stock |
|---|---|---|
| 5mg | $98 | In-stock |
| 10mg | $155 | In-stock |
| 25mg | $230 | In-stock |
| 50mg | $395 | In-stock |
| 100mg | $635 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-10521 |
| M.Wt: | 666.77 |
| Formula: | C36H38F4N4O2S |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 100 mg/mL |
Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer[1][2][3][4].
IC50 & Target:IC50: 0.25 nM (Lp-PLA2)[1]
In Vitro:Darapladib (5 μM; 6, 12 h) induces cell cycle arrest in glioma cells (C6 glioma cells and U251MG cells)[2].
Darapladib (5 μM; 3, 6 h) triggers cell apoptosis in glioma cells[2].
Darapladib (5 μM; 5, 15, 30, 60 and 90 min) induces an increase in phosphorylation of ERK1/2 proteins in glioma cells[2].
In Vivo:Darapladib (50 mg/kg; p.o.; once daily for 6 weeks) significantly inhibits serum Lp-PLA2 activity in LDLR-deficient mice[3].
Darapladib (50 mg/kg; p.o.; once daily for 6 weeks) decreases serum hs-CRP and IL-6 levels[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Darapladib
- Cat. No.:
- HY-10521
- Quantity:
Your information is safe with us.